BCR-ABL Inhibitor HS-10382

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable, allosteric tyrosine kinase inhibitor of the BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, BCR-ABL inhibitor HS-10382 targets and binds to the ABL myristoyl pocket, locking BCR-ABL into an inactive conformation, thereby inhibiting the activity of BCR-ABL and decreasing the proliferation of tumor cells. BCR-ABL fusion protein is an aberrantly activated tyrosine kinase produced by certain leukemia cells.

**Synonyms:** - BCR-ABL Tyrosine Kinase Inhibitor HS-10382 - HS 10382 - HS-10382 - HS10382 - TERN 701 - TERN-701 - TERN701